PharmaNutra SpA (PHN) Price & Analysis

Compare

11 Followers

PHN Stock Chart & Stats

€48.95

-€0.80(-1.51%)

At close: Jan 08 4:00 PM EST

€48.95

-€0.80(-1.51%)

Day’s Range― - ―

52-Week Range€38.75 - €60.00

Previous CloseN/A

Volume2.81K

Average Volume (3M)26.26K

Market Cap

€517.93M

Enterprise ValueN/A

Total Cash (Recent Filing)€21.96M

Total Debt (Recent Filing)€20.98M

Price to Earnings (P/E)29.4

Beta0.52

Next Earnings

Mar 13, 2026

EPS Estimate

0.62

Next Dividend Ex-DateN/A

Dividend Yield1.87%

Share Statistics

EPS (TTM)0.50

Shares Outstanding9,680,977

10 Day Avg. Volume13,505

30 Day Avg. Volume26,261

Financial Highlights & Ratios

PEG Ratio1.05

Price to Book (P/B)8.41

Price to Sales (P/S)4.50

P/FCF Ratio32.17

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€81.00

Price Target Upside65.47% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)2

Revenue Forecast (FY)€130.79M

Bulls Say, Bears Say

Bulls Say

Financial PerformancePharmanutra continues to deliver solid financial performances and outperform its reference markets.

Market ExpansionPharmanutra is expanding its market presence with significant contributions expected from new projects in the USA and China.

Sales GrowthThe group delivered strong results marked by double-digit revenue growth and continued progress of its long-term investment strategy.

Bears Say

Working Capital ImpactFCFO was fully absorbed by temporary working capital needs due to higher sales volumes and increased inventories, impacting the net financial position.

PharmaNutra SpA News

PharmaNutra SpA: Strong Growth, Strategic Success, and Undervalued Stock Justify Buy Rating

PharmaNutra SpA, the Healthcare sector company, was revisited by a Wall Street analyst on November 21. Analyst Corentin...

26d ago

PharmaNutra SpA: Strategic Growth and Strong Financials Justify Buy Rating

In a report released today, Giorgio Tavolini from Intermonte maintained a Buy rating on PharmaNutra SpA, with a...

1M ago

PharmaNutra SpA: Strong Financial Performance and Growth Potential Justify Buy Rating

PharmaNutra SpA, the Healthcare sector company, was revisited by a Wall Street analyst on October 14. Analyst Corentin...

2M ago

PharmaNutra SpA: Strong Buy Recommendation Amid Robust Growth and Strategic Expansion

Intermonte analyst Giorgio Tavolini maintained a Buy rating on PharmaNutra SpA on September 9 and set a price...

3M ago

PharmaNutra SpA: Strong International Growth and Strategic Market Expansion Drive Buy Recommendation

PharmaNutra SpA, the Healthcare sector company, was revisited by a Wall Street analyst on September 9. Analyst Corentin...

3M ago

PharmaNutra SpA: Strong Growth Potential and Strategic Expansion Drive Buy Rating

Intermonte analyst Giorgio Tavolini maintained a Buy rating on PharmaNutra SpA (PHN – Research Report) yesterday and set...

7M ago

PharmaNutra SpA: Strong International Sales and Financial Health Drive Buy Rating Despite Profitability Concerns

PharmaNutra SpA (PHN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday....

7M ago

PharmaNutra SpA (PHN) Declares Q2 Dividend: Important Details for Shareholders

PharmaNutra SpA (Milan: PHN) has declared, under its dividend policy, a yearly cash dividend in the amount of...

8M ago

PharmaNutra SpA: Promising Growth Prospects and Strategic Expansion Justify Buy Rating

In a report released yesterday, Daniele Alibrandi from Stifel Nicolaus reiterated a Buy rating on PharmaNutra SpA (PHN...

9M ago

PharmaNutra SpA: Strong Performance and Strategic Growth Drive Buy Rating

In a report released on March 17, Giorgio Tavolini from Intermonte maintained a Buy rating on PharmaNutra SpA...

9M ago

PHN FAQ

What was PharmaNutra SpA’s price range in the past 12 months?

PharmaNutra SpA lowest stock price was €38.75 and its highest was €60.00 in the past 12 months.

What is PharmaNutra SpA’s market cap?

PharmaNutra SpA’s market cap is €517.93M.

When is PharmaNutra SpA’s upcoming earnings report date?

PharmaNutra SpA’s upcoming earnings report date is Mar 13, 2026 which is in 83 days.

How were PharmaNutra SpA’s earnings last quarter?

PharmaNutra SpA released its earnings results on Nov 10, 2025. The company reported €0.5 earnings per share for the quarter, beating the consensus estimate of N/A by €0.5.

Is PharmaNutra SpA overvalued?

According to Wall Street analysts PharmaNutra SpA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does PharmaNutra SpA pay dividends?

PharmaNutra SpA pays a Annually dividend of €1 which represents an annual dividend yield of 1.87%. See more information on PharmaNutra SpA dividends here

What is PharmaNutra SpA’s EPS estimate?

PharmaNutra SpA’s EPS estimate is 0.62.

How many shares outstanding does PharmaNutra SpA have?

PharmaNutra SpA has 9,680,977 shares outstanding.

What happened to PharmaNutra SpA’s price movement after its last earnings report?

PharmaNutra SpA reported an EPS of €0.5 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.563%.

Which hedge fund is a major shareholder of PharmaNutra SpA?

Currently, no hedge funds are holding shares in IT:PHN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

PharmaNutra SpA

PharmaNutra SpA is an Italian pharmaceutical company specializing in the research, development, and commercialization of nutritional supplements and medical devices. The company operates primarily in the healthcare sector, focusing on innovative products that enhance human health and well-being. Its core offerings include iron-based supplements, minerals, and other nutritional products designed to address various health issues, particularly in the areas of sports nutrition, joint health, and women's health.

PharmaNutra SpA (PHN) Earnings & Revenues

Historic Earnings Reports

PHN Stock 12 Month Forecast

Average Price Target

€81.00

▲(65.47% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"38":"€38","50":"€50","62":"€62","74":"€74","86":"€86"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€85.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":81,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€81.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":74,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€74.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[38,50,62,74,86],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.9,59.06153846153846,61.223076923076924,63.38461538461539,65.54615384615384,67.70769230769231,69.86923076923077,72.03076923076924,74.1923076923077,76.35384615384615,78.51538461538462,80.67692307692307,82.83846153846154,{"y":85,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.9,58.753846153846155,60.607692307692304,62.46153846153846,64.31538461538462,66.16923076923077,68.02307692307693,69.87692307692308,71.73076923076923,73.58461538461538,75.43846153846154,77.29230769230769,79.14615384615385,{"y":81,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.9,58.215384615384615,59.53076923076923,60.84615384615385,62.16153846153846,63.47692307692308,64.79230769230769,66.1076923076923,67.42307692307692,68.73846153846154,70.05384615384615,71.36923076923077,72.68461538461538,{"y":74,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":53.41,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.21,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.11,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.7,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.82,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.8,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.85,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.3,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.1,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.15,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.9,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >